Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Okla. Plan B restriction blocked; CRN knocks disease claims via NAD; Facebook testimonial stings Vibrant Life

This article was originally published in The Tan Sheet

Executive Summary

Oklahoma judge blocks Plan B restrictions; CRN challenges disease claims via NAD; Lonza backs Alomune claims, ERSP says; Facebook testimonial prompts Vibrant Life warning; Rx adulterant recalls, alerts; and Codex adopts 11 nutrient reference values;.

You may also be interested in...



Firms Navigate Social Media Safely Following Loss Of Facebook Protection

Several drug companies may have shuttered their Facebook pages prematurely in August after the social networking site revoked their exclusive privilege to block consumer comments on their walls.

International Panel’s Nutrient Value Guideline May Boost Supplement Exports

Dietary supplement firms soon could export products internationally without having to reformulate to accommodate local nutrient value regulations.

Pink Sheet Podcast: US FDA’s Chloroquine EUA And Coronavirus Treatment Accelerator, Novartis Receives No Penalty For Zolgensma Problems

Pink Sheet reporters and editors discuss the effects of the chloroquine emergency use authorization, FDA efforts to speed coronavirus treatment development, and the agency decision against penalizing Novartis over Zolgensma’s data integrity problems. 

Topics

Related Companies

UsernamePublicRestriction

Register

PS106577

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel